Boardroom Alpha
Meeting calendar
STE · Annual meeting · Thursday, July 31, 2025

Steris PLC

10 nominees · 8 ballot items.

Election of directors and Irish-law corporate governance and other matters, including advisory Say-on-Pay, auditor ratifications, and Irish-authority renewals; 8 proposals in total (Proposals 1-7 are ordinary resolutions and Proposal 8 is for other business).

Market cap
$20.7B
1Y TSR
-12.5%
Board grade
C+
Record date
Jun 2, 2025
Filing
DEF 14A
Meeting concluded · Jul 31, 2025

Follow how the vote landed and what changed on Steris PLC’s board — director track records, governance grades, and ongoing monitoring — on the Boardroom Alpha platform.

Proposals

On the ballot8

  1. 1

    Nominees for Election as Directors

    ManagementBoard: FOR

    To elect ten director nominees to serve as directors of the Company through the next annual general meeting, subject to resignation or removal.

  2. 2

    Ratification of Appointment of Independent Registered Public Accounting Firm

    ManagementBoard: FOR

    To ratify the appointment of Ernst & Young LLP as the Company's independent registered public accounting firm for the fiscal year ending March 31, 2026.

  3. 3

    Appointment of Ernst & Young Chartered Accountants as the Company’s Irish Statutory Auditor

    ManagementBoard: FOR

    To appoint Ernst & Young Chartered Accountants as the Company’s Irish statutory auditor to hold office until the conclusion of the next annual general meeting.

  4. 4

    Authorization to Determine Irish Statutory Auditor Remuneration

    ManagementBoard: FOR

    To authorize the Board of Directors or the Audit Committee to determine the remuneration of Ernst & Young Chartered Accountants as the Company’s Irish statutory auditor.

  5. 5

    Advisory Resolution on Named Executive Officer Compensation

    ManagementBoard: FOR

    To approve, on a non-binding advisory basis, the compensation of the Company’s named executive officers as disclosed in the Proxy Statement.

  6. 6

    Renewal of the Board’s Authority to Issue Shares Under Irish Law

    ManagementBoard: FOR

    To renew the Board’s authority to issue authorized but unissued shares up to ~20% of the existing issued ordinary share capital, and to hold this authority until the next AGM or 15 months from the Meeting date.

  7. 7

    Renewal of the Board’s Authority to Opt-Out of Statutory Pre-Emption Rights Under Irish Law

    ManagementBoard: FOR

    To renew the Board’s authority to opt-out of statutory pre-emption rights regarding the issuance of shares for cash, up to ~20% of issued share capital with conditions for acquisitions or specified capital investments, and to expire with the next AGM or 15 months from the Meeting date.

  8. 8

    Resolution to Transact Such Other Business As May Come Before the Meeting

    Management

    To transact such other business as may properly come before the Annual Meeting or any adjournment thereof; the Board is not aware of any other matters.

Director elections

Nominees on the ballot10

Independent
Tenure on this board
21.3 yrs
Also a director at
Ufp Technologies Inc (UFPT)
Independent
Tenure on this board
5.2 yrs
Also a director at
Unisys Corp (UIS)Owens Corning (OC)
Independent
Tenure on this board
0.9 yrs
Also a director at
Zimmer Biomet Holdings Inc (ZBH)
Independent
Tenure on this board
21.0 yrs
Also a director at
Baker Hughes Co (BKR)
Ownership

Top institutional holders10

Latest 13F quarter
1VANGUARD CAPITAL MANAGEMENT LLC6.5%6,366,378$1.4B
2STATE STREET CORP5.1%4,991,868$1.1B
3VANGUARD PORTFOLIO MANAGEMENT LLC5.1%4,950,040$1.1B
4BlackRock, Inc.3.9%3,767,012$833M
5MORGAN STANLEY3.2%3,149,995$697M
6MASSACHUSETTS FINANCIAL SERVICES CO /MA/2.8%2,772,859$613M
7WELLINGTON MANAGEMENT GROUP LLP2.6%2,546,945$563M
8Orbis Allan Gray Ltd2.5%2,419,984$535M
9GENERATION INVESTMENT MANAGEMENT LLP2.4%2,308,459$510M
10GEODE CAPITAL MANAGEMENT, LLC2.3%2,266,441$499M
Filings

Recent key filings

Periodic reports
Definitive proxies
Reference

Frequently asked questions

When is the Steris PLC 2025 annual meeting?
Steris PLC (STE) holds its 2025 annual shareholder meeting on Thursday, July 31, 2025.
What is the record date for the Steris PLC 2025 meeting?
The record date for the Steris PLC 2025 meeting is Monday, June 2, 2025. Shareholders of record on or before that date are eligible to vote.
Who are the director nominees for Steris PLC's 2025 meeting?
The board is presenting 10 director nominees at the Steris PLC 2025 meeting, listed with their independence status and background.
What proposals will shareholders vote on at the Steris PLC 2025 meeting?
Shareholders will vote on 8 proposals at the Steris PLC 2025 meeting, each tagged with who proposed it and the board's recommendation.
Disclaimer

The opinions and information contained herein have been obtained or derived from sources believed to be reliable, but Boardroom Alpha cannot guarantee its accuracy and completeness, and that of the opinions based thereon.

This report contains opinions and is provided for informational purposes only – it does not constitute investment, legal or tax advice. You should not rely solely upon the research herein for purposes of transacting securities or other investments, and you are encouraged to conduct your own research and due diligence, and to seek the advice of a qualified securities professional before you make any investment.

None of the information contained in this report constitutes, or is intended to constitute a recommendation by Boardroom Alpha of any particular security or trading strategy or a determination by Boardroom Alpha that any security or trading strategy is suitable for any specific person. To the extent any of the information contained herein may be deemed to be investment advice, such information is impersonal and not tailored to the investment needs of any specific person.

No representation or warranty, expressed or implied, is made on behalf of Boardroom Alpha as to the accuracy or completeness of the information contained herein. Boardroom Alpha does not accept any liability for any direct, indirect or consequential loss or damage suffered by any person as a result of relying on all or any part of this research and any liability is expressly disclaimed.

Full disclaimer